Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.

Ther Adv Med Oncol · 2026 · PMC13428147 · PMID 42542772

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a numerical trendp = 0.08so close (0.05 < p ≤ 0.1)

Combined treatment showed a numerical trend toward improved ORR (33.3% vs 16.0%, p = 0.08), but did not significantly prolong PFS compared to surufatinib monotherapy (9.7 vs 9.4 months, p = 0.64).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.